LH Stock Chart & Stats
$4705.14
$0.00(0.00%)
At close: 4:00 PM EDT
$4705.14
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3,000.00 - $5,245.61
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$428.77B
Enterprise Value$29.60K
Total Cash (Recent Filing)$141.80M
Total Debt (Recent Filing)$6.77B
Price to Earnings (P/E)25.6
Beta0.20
Next Earnings
Oct 22, 2026EPS Estimate
79.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.17
Shares Outstanding81,100,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)2.42
Price to Sales (P/S)1.50
P/FCF Ratio17.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5,812.57Price Target Upside23.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)311.88
Revenue Forecast (FY)$250.70B
Bulls Say, Bears Say
Bulls Say
Diversified Healthcare Services ModelLabcorp’s two-segment model serves diverse healthcare and biopharma customers, reducing reliance on any single end market. Diagnostics provides recurring testing demand, while Drug Development adds exposure to outsourced clinical research and creates broader opportunities for cross-cycle growth.
Biopharma Backlog And Demand VisibilityThe sizable BLS backlog provides meaningful forward revenue visibility and supports utilization across Labcorp’s laboratory infrastructure. Book-to-bill above one also indicates demand is replenishing delivered work, which can sustain growth and improve planning over the next several quarters.
Expanded Global Laboratory CapabilitiesMLM strengthens Labcorp’s central-laboratory footprint, geographic reach, and biomarker capabilities in clinical research. A broader owned network can improve the company’s ability to serve multinational sponsors, deepen its scientific offering, and reinforce its competitive position in outsourced trials.
Bears Say
Margins Remain Below Prior PeaksRecent profitability has improved, but margins remain materially below earlier peak levels, showing that earnings recovery is incomplete. Persistent compression can limit internal funding for innovation and acquisitions, while leaving results more exposed to reimbursement, mix, and operating-cost pressure.
Free Cash Flow Has WeakenedLabcorp generates substantial cash, but the recent decline and less-than-one-times operating-cash-flow conversion of net income reduce the quality and predictability of funding. Continued variability could constrain debt reduction, acquisitions, capital investment, or shareholder returns if operating needs rise.
Meaningful Leverage And Limited CashAlthough leverage is described as manageable, the absolute debt burden and relatively low cash balance reduce financial flexibility. If demand or cash conversion weakens, more operating cash may need to support interest, maturities, or investment, limiting capacity to pursue growth initiatives.
Labcorp Holdings News
LH FAQ
What was Labcorp Holdings’s price range in the past 12 months?
Labcorp Holdings lowest stock price was $3000.00 and its highest was $5245.61 in the past 12 months.
What is Labcorp Holdings’s market cap?
Labcorp Holdings’s market cap is $428.77B.
When is Labcorp Holdings’s upcoming earnings report date?
Labcorp Holdings’s upcoming earnings report date is Oct 22, 2026 which is in 39 days.
How were Labcorp Holdings’s earnings last quarter?
Labcorp Holdings released its earnings results on Jul 30, 2026. The company reported $84.809 earnings per share for the quarter, beating the consensus estimate of $81.223 by $3.586.
Is Labcorp Holdings overvalued?
According to Wall Street analysts Labcorp Holdings’s price is currently Undervalued.
Does Labcorp Holdings pay dividends?
Labcorp Holdings does not currently pay dividends.
What is Labcorp Holdings’s EPS estimate?
Labcorp Holdings’s EPS estimate is 79.08.
How many shares outstanding does Labcorp Holdings have?
Labcorp Holdings has 81,100,000 shares outstanding.
What happened to Labcorp Holdings’s price movement after its last earnings report?
Labcorp Holdings reported an EPS of $84.809 in its last earnings report, beating expectations of $81.223. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Labcorp Holdings?
Currently, no hedge funds are holding shares in MX:LH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Labcorp Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5,812.57 (23.54% Upside)
$5,812.57 (23.54% Upside)
Blogger Sentiment
Neutral
MX:LH Sentiment 75%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth $12.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.50%
12-Months-Change
Fundamentals
Return on Equity
0.86%
Trailing 12-Months
Asset Growth
2.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Labcorp Holdings
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
LH Company Deck
LH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational and financial quarter: revenue growth, margin expansion, double-digit adjusted EPS growth, raised guidance, robust BLS backlog and book-to-bill, and multiple product/partnership launches. Headwinds highlighted were a meaningful quarter-over-quarter drop in free cash flow (timing and capex), a modest ACA-related volume headwind (~30 bps), prior and improving Early Development softness, higher patient-pay mix, and elevated absolute debt with relatively low cash on hand. On balance the positives around revenue, margins, guidance increases, product/market progress, and capital returns materially outweigh the cited challenges.View all MX:LH earnings summariesLH Revenue Breakdown
77.96% Dx
22.21% BLS
-0.16% Intercompany eliminations
LH Stock 12 Month Forecast
Average Price Target
$5,812.57
▲(23.54% Upside)